Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01791543
Other study ID # 2013P000304
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date May 27, 2022

Study information

Verified date January 2023
Source Vanderbilt University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess the effectiveness and safety of a new device called an Intramural Needle Ablation Catheter (INA catheter). The INA catheter is used for locating and ablating ventricular arrhythmias that have failed standard radiofrequency ablation. This approach is desirable because some people have ventricular arrhythmias that originate deep within the heart muscle where it is not abolished by ablation with standard catheters. The investigators seek to determine whether the INA catheter can potentially help people who have ventricular arrhythmias that have failed standard radiofrequency ablation. The investigators also want to determine if it is likely to be safe, without excessive side effects.


Recruitment information / eligibility

Status Completed
Enrollment 115
Est. completion date May 27, 2022
Est. primary completion date May 27, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Monomorphic ventricular tachycardia (VT) or incessant ventricular arrhythmia (defined as >20% of beats due to ventricular arrhythmia including unifocal premature ventricular contractions (PVCs ), couplets, nonsustained VT) that is causing a decline in left ventricular (LV) ejection fraction to less than 0.50. Arrhythmia meets the following criteria: 1. Ventricular arrhythmia is recurrent and symptomatic 2. prior antiarrhythmic drug therapy has failed due to recurrent ventricular arrhythmia, toxicity, or intolerance - Age 18 or older - Left ventricular (LV) ejection fraction > 0.10 as estimated by echocardiography or contrast ventriculography within the previous 90 days - Failed prior VT or PVC ablation due to spontaneous recurrence of the arrhythmia or frequent PVCs. - Able and willing to comply with all pre-, post-, and follow-up testing and requirements - Signed Informed Consent Exclusion Criteria: - Patients with idiopathic VT defined as VT that originates from a region without evidence of scar detected by MRI or voltage mapping in a patient without other evidence of heart disease that is not causing significant depression of ventricular function. - Definite protruding left ventricular thrombus on pre-ablation echocardiography when LV ablation is required. - Thrombotic myocardial infarction within the preceding two (2) months. - Other disease process that is likely to limit survival to less than 12 months. - Class IV heart failure, unless heart failure is due to frequent or incessant VT. - Contraindication to heparin. - Allergy to radiographic contrast dye. - Severe aortic stenosis - Severe mitral regurgitation with a flail mitral valve leaflet. - Significant congenital anomaly or medical problem that in the opinion of the principal investigator would preclude enrollment into the study. - Enrolled in another investigational study evaluating a drug or device. - Unstable angina that is not due to frequent or incessant VT. - Women who are pregnant. - Thrombocytopenia (platelet count < 50,000) or coagulopathy. - Acute non-cardiovascular illness or systemic infection. - Cardiogenic shock unless it is due to incessant VT

Study Design


Intervention

Device:
Intramural Needle Ablation Catheter


Locations

Country Name City State
United States Brigham and Women's Hospital Boston Massachusetts
United States Vanderbilt Heart and Vascular Institute Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
William Stevenson

Country where clinical trial is conducted

United States, 

References & Publications (4)

Sapp JL, Beeckler C, Pike R, Parkash R, Gray CJ, Zeppenfeld K, Kuriachan V, Stevenson WG. Initial human feasibility of infusion needle catheter ablation for refractory ventricular tachycardia. Circulation. 2013 Nov 19;128(21):2289-95. doi: 10.1161/CIRCULATIONAHA.113.003423. Epub 2013 Sep 13. — View Citation

Sapp JL, Cooper JM, Zei P, Stevenson WG. Large radiofrequency ablation lesions can be created with a retractable infusion-needle catheter. J Cardiovasc Electrophysiol. 2006 Jun;17(6):657-61. doi: 10.1111/j.1540-8167.2006.00439.x. — View Citation

Schaeffer B, Tanigawa S, Nakamura T, Muthalaly RG, Sapp J, John R, Ghidoli D, Pellegrini C, Tedrow U, Stevenson WG. Characteristics of myocardial tissue staining and lesion creation with an infusion-needle ablation catheter for the treatment of ventricular tachycardia in humans. Heart Rhythm. 2020 Mar;17(3):398-405. doi: 10.1016/j.hrthm.2019.10.007. Epub 2019 Oct 8. — View Citation

Stevenson WG, Tedrow UB, Reddy V, AbdelWahab A, Dukkipati S, John RM, Fujii A, Schaeffer B, Tanigawa S, Elsokkari I, Koruth J, Nakamura T, Naniwadekar A, Ghidoli D, Pellegrini C, Sapp JL. Infusion Needle Radiofrequency Ablation for Treatment of Refractory — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Without Hospitalization for Ventricular Tachycardia (VT) During 6 Months Freedom from hospitalization for recurrent Ventricular Tachycardia during the 6 months following ablation for VT. 6 months
Primary Number of Participants With No Serious Adverse Events Absence of serious adverse events that are potentially device related and occur within 30 days of the ablation procedure 30 days
Primary Number of Subjects Ablated for Nonsustained Arrhythmias Who Had a Reduction to Less Than 5000 Arrhythmia Beats Daily Number of subjects who had ablation for nonsustained arrhythmias with ventricular dysfunction who had a decrease in ambient ventricular arrhythmia to < 5000 ventricular beats daily. 6 months
Secondary Number of Subjects With Acute Abolition of at Least One Clinical Inducible Ventricular Tachycardia or Targeted Nonsustained Arrhythmia Defined as termination of at least one clinical or presumptive clinical monomorphic VT by Radiofrequency ablation and/or rendering that VT no longer inducible or abolition of a targeted nonsustained arrhythmia. Baseline to end of the ablation procedure (approximately 5 hours)
See also
  Status Clinical Trial Phase
Recruiting NCT03453645 - Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Completed NCT05791032 - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study N/A
Completed NCT04011631 - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. N/A
Recruiting NCT03536052 - Ablation at Virtual-hEart pRedicted Targets for VT N/A
Not yet recruiting NCT06063811 - Ventricular Tachycardia Ablation in LVAD Patients
Enrolling by invitation NCT02962076 - Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia Early Phase 1
Not yet recruiting NCT02784912 - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation N/A
Terminated NCT02891863 - Low Energy Therapy to Convert Ventricular Tachycardias Phase 0
Terminated NCT01546207 - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia N/A
Completed NCT01294267 - Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation N/A
Terminated NCT00383799 - Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia Phase 4
Completed NCT04884100 - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening N/A
Completed NCT04642963 - Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia N/A
Recruiting NCT05377216 - Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation Early Phase 1
Not yet recruiting NCT04990089 - VIVO European Observational Registry
Completed NCT04065893 - Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
Recruiting NCT03631303 - Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias
Recruiting NCT03611465 - Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts N/A
Suspended NCT05478213 - Ventricular Tachycardia Mechanisms N/A